Merck: CHMP greenlights Keytruda in pleural mesothelioma

(CercleFinance.com) - Merck announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for the approval of Keytruda (pembrolizumab), in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adults with unresectable malignant non-epithelioid pleural mesothelioma.


This recommendation is based on the results of a pivotal study (IND.227/KEYNOTE-483), which showed a significant improvement in overall survival compared with chemotherapy alone.

The European Commission's final decision is expected in Q4 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.